Travere Therapeutics (NASDAQ:TVTX) Insider Elizabeth Reed Sells 2,076 Shares

Key Points

• Insider sale: Elizabeth Reed sold 2,076 shares at an average price of $43.95 (≈$91,240) under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding, leaving her with 105,211 shares (a 1.93% reduction).
• Quarterly results: Travere posted Q1 EPS of $0.05, beating consensus of -$0.24, while revenue was $127.2M (below the $136.23M estimate) but up 55.6% year‑over‑year.
• Positive analyst and institutional momentum: Several firms raised price targets (e.g., TD Cowen to $60, Wells Fargo to $50) and the stock carries a "Moderate Buy" consensus with a $47.83 target, while major institutions have been increasing their stakes.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Elizabeth Reed sold 2,076 shares of the business's stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total value of $91,240.20. Following the sale, the insider directly owned 105,211 shares of the company's stock, valued at approximately $4,624,023.45. This trade represents a 1.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Trading Down 0.2%

TVTX stock traded down $0.10 during trading on Wednesday, reaching $44.70. 2,390,035 shares of the stock traded hands, compared to its average volume of 2,890,153. The business's 50 day moving average price is $32.59 and its 200-day moving average price is $32.83. Travere Therapeutics, Inc. has a 52-week low of $13.88 and a 52-week high of $48.61. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. The firm has a market capitalization of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The firm had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same quarter in the previous year, the business earned ($0.47) earnings per share. The firm's quarterly revenue was up 55.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Travere Therapeutics by 10.3% during the third quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company's stock worth $158,059,000 after purchasing an additional 619,085 shares in the last quarter. State Street Corp lifted its stake in shares of Travere Therapeutics by 47.8% in the fourth quarter. State Street Corp now owns 4,756,666 shares of the company's stock worth $181,752,000 after acquiring an additional 1,538,827 shares in the last quarter. Perceptive Advisors LLC lifted its stake in shares of Travere Therapeutics by 12.7% in the fourth quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company's stock worth $163,469,000 after acquiring an additional 483,565 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of Travere Therapeutics by 27.4% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company's stock worth $41,203,000 after acquiring an additional 599,102 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Travere Therapeutics by 28.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company's stock worth $85,849,000 after acquiring an additional 494,665 shares in the last quarter.

Wall Street Analysts Forecast Growth

TVTX has been the topic of a number of recent research reports. Piper Sandler upgraded Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 price objective on the stock in a research note on Tuesday, April 14th. Wells Fargo & Company boosted their price objective on Travere Therapeutics from $40.00 to $50.00 and gave the stock an "overweight" rating in a research note on Wednesday. JPMorgan Chase & Co. reduced their price objective on Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 25th. TD Cowen boosted their price objective on Travere Therapeutics from $45.00 to $60.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Wedbush boosted their price objective on Travere Therapeutics from $53.00 to $55.00 and gave the stock an "outperform" rating in a research note on Tuesday. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $47.83.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.